Orlando—The roles played by anemia and iron deficiency in cardiovascular risk remain unclear, and findings on how treatment of these conditions affects such risk have further complicated the puzzle.
Anemia serves as a biomarker because lower hemoglobin levels are associated with higher rates of cardiovascular and renal events. One treatment strategy is to use erythropoiesis-stimulating agents (ESAs) to increase hemoglobin levels. ESAs have been found to reduce the need for red-cell transfusions and improve such patient quality-of-life factors as fatigue. But until lately, ESAs had not been tested against a placebo, so their effects on hard clinical end points such as reducing the risk of a cardiovascular event or death had remained unknown.
Graphic Jump Location
Agents that stimulate red blood cell production lessen the need for transfusions but do not reduce risk of cardiovascular events or death in certain patients, a new study found.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Users' Guides to the Medical Literature
Iron Deficiency Anemia
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.